Sprint Bioscience AB (SPRINT) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.182x

Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has a cash flow conversion efficiency ratio of -0.182x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-19.29 Million ≈ $-2.08 Million USD) by net assets (Skr106.29 Million ≈ $11.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sprint Bioscience AB (SPRINT) market capitalisation for the company's overall valuation and market capitalisation.

Sprint Bioscience AB - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Sprint Bioscience AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Sprint Bioscience AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sprint Bioscience AB ranked by their cash flow conversion efficiency. Explore SPRINT cash flow quality score to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Guyoung Technology Co. Ltd KQ:053270	0.048x
Tamul Multimedia Co. Ltd KQ:093640	-0.041x
Central Petroleum Ltd AU:CTP	0.120x
Wellbiotec Co. Ltd. KO:010600	-0.033x
Wiseway Group Ltd AU:WWG	0.102x
Cineline India Limited NSE:CINELINE	0.036x
Alternative Investment Trust AU:AIQ	0.026x
NEXTCHIP Co. Ltd KQ:092600	-0.132x

Annual Cash Flow Conversion Efficiency for Sprint Bioscience AB (2012–2025)

The table below shows the annual cash flow conversion efficiency of Sprint Bioscience AB from 2012 to 2025. View Sprint Bioscience AB (SPRINT) share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr119.18 Million ≈ $12.83 Million	Skr83.53 Million ≈ $8.99 Million	0.701x	+127.83%
2024-12-31	Skr9.27 Million ≈ $997.82K	Skr-23.36 Million ≈ $-2.51 Million	-2.519x	-405.90%
2023-12-31	Skr27.77 Million ≈ $2.99 Million	Skr22.87 Million ≈ $2.46 Million	0.823x	+139.31%
2022-12-31	Skr28.19 Million ≈ $3.03 Million	Skr-59.05 Million ≈ $-6.36 Million	-2.095x	-267.93%
2021-12-31	Skr70.45 Million ≈ $7.58 Million	Skr-40.12 Million ≈ $-4.32 Million	-0.569x	+83.84%
2020-12-31	Skr9.14 Million ≈ $984.04K	Skr-32.22 Million ≈ $-3.47 Million	-3.524x	-38.64%
2019-12-31	Skr11.02 Million ≈ $1.19 Million	Skr-28.00 Million ≈ $-3.01 Million	-2.542x	-396.07%
2018-12-31	Skr37.24 Million ≈ $4.01 Million	Skr-19.08 Million ≈ $-2.05 Million	-0.512x	+37.56%
2017-12-31	Skr28.09 Million ≈ $3.02 Million	Skr-23.05 Million ≈ $-2.48 Million	-0.821x	-394.71%
2016-12-31	Skr28.49 Million ≈ $3.07 Million	Skr7.93 Million ≈ $853.92K	0.278x	+61.03%
2015-12-31	Skr4.82 Million ≈ $518.74K	Skr833.54K ≈ $89.70K	0.173x	+132.66%
2014-12-31	Skr20.32 Million ≈ $2.19 Million	Skr-10.76 Million ≈ $-1.16 Million	-0.529x	+50.07%
2013-12-31	Skr3.36 Million ≈ $361.91K	Skr-3.57 Million ≈ $-383.76K	-1.060x	+49.25%
2012-12-31	Skr1.10 Million ≈ $118.06K	Skr-2.29 Million ≈ $-246.66K	-2.089x	--

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology

Market Cap

$33.50 Million

Skr311.27 Million SEK

Market Cap Rank

#23483 Global

#444 in Sweden

Share Price

Skr2.95

Change (1 day)

+0.00%

52-Week Range

Skr0.56 - Skr4.49

All Time High

Skr47.75